Draft:Michael Rosenblatt

Michael Rosenblatt is a physician and biomedical scientist who has held various leadership roles in both academic medicine and the biopharmaceutical industry.

Leadership roles in academic medicine

Dr. Rosenblatt served as Dean of Tufts University School of Medicine from 2003-09. He previously held a variety of leadership positions at Harvard Medical School and its affiliated teaching hospitals. These included serving as Chief of the Endocrine Unit at Massachusetts General Hospital (1981-84), Director of the Harvard-MIT Division of Health Sciences and Technology (1992-98), Founding Executive Director of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center (1996-2000), Harvard Faculty Dean for Academic Programs at Beth Israel Deaconess Medical Center (1996-2000), and President of Beth Israel Deaconess Medical Center (1999-2001). During his time at Harvard Medical School, he has at separate times held the Robert Ebert Professorship in Molecular Medicine and the George R. Minot Professorship of Medicine. Dr. Rosenblatt currently serves on the Harvard Medical School Board of Fellows.

Leadership roles in the biopharmaceutical industry

Interspersed between positions in academic medicine, Dr. Rosenblatt has held several leadership positions at Merck. These included Vice President for Biological Research and Molecular Biology (1984-89), Senior Vice President for Research (1989-92), and Executive Vice President and Chief Medical Officer (2009-16). He has also served on the scientific advisory board and the board of directors of multiple domestic and international biotechnology companies. From 2016-21 he was Chief Medical Officer at Flagship Pioneering, the venture capital firm that created Moderna. During this period, he contributed to Moderna’s coronavirus vaccine efforts through serving on or chairing several Moderna committees.

Research contributions

As Senior Vice President for Research at Merck, he co-led the development of alendronate (Fosamax), now the leading therapy worldwide for osteoporosis. Later, as Chief Medical Officer at Merck, he was part of the team that developed pembrolizumab (Keytruda). He has also written extensively about biomedical innovation and the interface between academia and industry.

Honors, awards, and affiliations

• American Society of Clinical Investigation
• Association of American Physicians
• Fellow, American Association for the Advancement of Science
• Fellow, American College of Physicians
• President, American Society of Bone and Mineral Metabolism
• Fuller Albright Award from the American Society for Bone and Mineral Research (for work on parathyroid hormone)
• Vincent du Vigneaud Award in peptide chemistry and biology from the American Peptide Society
• Chairman’s Award from Merck

Education and training

Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia University and his medical degree magna cum laude from Harvard Medical School. He was a resident in internal medicine and a fellow in endocrinology at Massachusetts General Hospital.